secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sensei Biotherapeutics, Inc. (SNSE)
CIK:        0001829802
Form:       8-K
Filed at:   2024-05-23T23:59:59+00:00
Accession:  0001193125-24-146093
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sensei Biotherapeutics reports Phase 1 data for SNS-101: 59% tumor reduction in MSS endometrial cancer, well tolerated
--------------------------------------------------------------------------------

- Confirmed partial response (59% decrease) in an MSS endometrial cancer patient on SNS-101 plus cemiplimab; remains on study at 30+ weeks.
- No dose-limiting toxicities; most AEs grade 1-2; mild cytokine release syndrome at highest dose manageable.
- PK profile shows linear elimination and dose-proportional exposure, supporting once-every-3-week dosing.
- Tumor regression observed in MSS CRC (27%), pembrolizumab-resistant RCC (18%), and HPV+ head & neck cancer (17%).
- Company expects initial dose expansion data and end-of-Phase 1 FDA meeting by end of 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829802/000119312524146093/0001193125-24-146093-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829802/000119312524146093/d830013d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-146093

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer